article thumbnail

The plant virus that trains your immune system to kill cancer

Science Daily: Pharmacology News

A virus from humble black-eyed peas is showing extraordinary promise in the fight against cancer. Unlike other plant viruses, the cowpea mosaic virus (CPMV) can awaken the human immune system and transform it into a cancer-fighting powerhouse, without infecting human cells.

article thumbnail

This tiny lung-on-a-chip could predict—and fight—the next pandemic

Science Daily: Pharmacology News

Powered by isogenic induced pluripotent stem cells (iPSCs), the system offers a high-fidelity way to model personalized immune responses and test drug effectiveness. This innovation opens the door to precision medicine, deeper understanding of emerging viruses, and even modeling of other organs in the future.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The future of CNS drug development: signs of real progress

Drug Target Review

Due to off-target effects, tissue accumulation and immune responses, ASOs face significant challenges, especially for preclinical safety assessments. Viral vectors use a virus’s blueprint to deliver genetic material into cells. However, ASOs cannot cross blood-CNS barriers so are often delivered intrathecally.

article thumbnail

Sarepta Strengthens ELEVIDYS Safety Measures for Non-Ambulatory Duchenne Patients

The Pharma Data

This independent expert panel will aid in evaluating a new, enhanced immunosuppressive regimen meant to help ease the body’s adaptive immune response — a process suspected to contribute to the elevated liver enzyme abnormalities and related events that have been observed in a small number of patients following treatment with AAV-based gene therapy.

article thumbnail

A Visual Guide to Gene Delivery

Codon

And even if all these economic hurdles are overcome, there are still three main technical challenges to solve: cargo capacity, specificity, and immune response. Some diseases are caused by mutations in large genes that exceed the packaging limits of existing vectors like adeno-associated virus (AAV).

article thumbnail

Roche shares Elevidys safety update in non-ambulatory Duchenne muscular dystrophy patients

The Pharma Data

This update comes after two cases of fatal acute liver failure (ALF) were reported in non-ambulatory DMD patients who received Elevidys, a phenomenon that underscores the ongoing complexities and safety signals related to adeno-associated virus (AAV)-mediated gene therapy.

article thumbnail

Sanofi Speeds Up Beyfortus Shipments Ahead of 2025-2026 RSV Season

The Pharma Data

Sanofi Ramps Up Early Global Distribution of Beyfortus to Meet Growing RSV Season Demand, Enhancing Protection for Infants Worldwide In a proactive move to ensure readiness for the 2025-2026 respiratory syncytial virus (RSV) season, Sanofi has announced that shipments of Beyfortus® (nirsevimab) will begin in early Q3 2025.